Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06897605

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Led by Mansoura University · Updated on 2025-04-02

80

Participants Needed

1

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

CONDITIONS

Official Title

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 65 18 years with CKD stage III or IV
  • Anemia of CKD with hemoglobin level < 11.5 g/dL
  • Receiving erythropoiesis-stimulating agent therapy
Not Eligible

You will not qualify if you...

  • Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes
  • Severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma
  • Acute heart failure, acute myocardial infarction, or stroke within 6 months before enrollment
  • Current malignancies or history of malignancy within the past 2 years
  • Diagnosed with pure red cell aplasia
  • Severe gastrointestinal bleeding
  • Pregnant or lactating females

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Urology and Nephrology Center

Al Mansurah, Egypt

Actively Recruiting

Loading map...

Research Team

B

Basma M. Sayed Ahmed, M.Sc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here